Interestingly, heterozygous loss or low expression of IKBKB is associated to mutations in TP53 and to impaired overall survival in breast tumors (Figure 2A) and in Head and Neck Squamous Cell Carcinomas (HNSCCs) (Figure 2B). Here, IKBKB is linked to breast neoplasm.